Cosmo Pharmaceuticals Valuation
Is COPN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of COPN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COPN (€67.5) is trading below our estimate of fair value (€802.22)
Significantly Below Fair Value: COPN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COPN?
Key metric: As COPN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is COPN's PE Ratio? | |
|---|---|
| PE Ratio | 15.6x |
| Earnings | €69.57m |
| Market Cap | €1.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.1x |
| Enterprise Value/EBITDA | 9.5x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does COPN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 46.1x | ||
A237690 ST PharmLtd | 55.8x | 33.5% | ₩1.8t |
COLL Collegium Pharmaceutical | 11.2x | 22.0% | US$990.4m |
605116 Aurisco PharmaceuticalLtd | 25.2x | 27.4% | CN¥8.6b |
AMIORG Ami Organics | 92.2x | 42.1% | ₹85.9b |
COPN Cosmo Pharmaceuticals | 15.6x | 17.2% | €1.0b |
Price-To-Earnings vs Peers: COPN is good value based on its Price-To-Earnings Ratio (15.6x) compared to the peer average (46.1x).
Price to Earnings Ratio vs Industry
How does COPN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: COPN is good value based on its Price-To-Earnings Ratio (15.6x) compared to the European Pharmaceuticals industry average (19.7x).
Price to Earnings Ratio vs Fair Ratio
What is COPN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COPN's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €67.50 | €103.90 +53.9% | 22.2% | €141.47 | €84.27 | n/a | 4 |
| Nov ’25 | €72.50 | €103.15 +42.3% | 23.0% | €141.47 | €81.29 | n/a | 4 |
| Oct ’25 | €81.00 | €103.19 +27.4% | 23.1% | €141.64 | €81.29 | n/a | 4 |
| Sep ’25 | n/a | €103.04 0% | 22.9% | €141.03 | €81.29 | n/a | 4 |
| Aug ’25 | n/a | €103.04 0% | 22.9% | €141.03 | €81.29 | n/a | 4 |
| Jul ’25 | n/a | €96.16 0% | 15.2% | €116.41 | €80.94 | n/a | 4 |
| Jun ’25 | n/a | €94.72 0% | 13.5% | €111.01 | €80.94 | n/a | 4 |
| May ’25 | n/a | €94.72 0% | 13.5% | €111.01 | €80.94 | n/a | 4 |
| Apr ’25 | n/a | €94.95 0% | 13.7% | €111.67 | €80.94 | n/a | 4 |
| Mar ’25 | n/a | €81.85 0% | 10.0% | €89.96 | €70.67 | n/a | 3 |
| Feb ’25 | n/a | €81.85 0% | 10.0% | €89.96 | €70.67 | n/a | 3 |
| Jan ’25 | n/a | €77.61 0% | 11.3% | €89.96 | €70.67 | n/a | 3 |
| Dec ’24 | n/a | €76.50 0% | 10.7% | €88.03 | €70.67 | n/a | 3 |
| Nov ’24 | n/a | €76.46 0% | 10.6% | €87.95 | €70.67 | €72.50 | 3 |
| Oct ’24 | n/a | €76.46 0% | 10.6% | €87.95 | €70.67 | €81.00 | 3 |
| Sep ’24 | n/a | €71.21 0% | 17.2% | €89.00 | €54.40 | n/a | 4 |
| Aug ’24 | n/a | €77.14 0% | 10.1% | €89.00 | €69.58 | n/a | 4 |
| Jul ’24 | n/a | €79.24 0% | 7.9% | €87.10 | €69.58 | n/a | 4 |
| Jun ’24 | n/a | €81.79 0% | 12.9% | €98.16 | €68.72 | n/a | 4 |
| May ’24 | n/a | €81.79 0% | 12.9% | €98.16 | €68.72 | n/a | 4 |
| Apr ’24 | n/a | €82.78 0% | 12.6% | €98.16 | €68.72 | n/a | 4 |
| Mar ’24 | n/a | €82.59 0% | 12.8% | €98.27 | €68.72 | n/a | 4 |
| Feb ’24 | n/a | €83.74 0% | 12.3% | €99.97 | €71.63 | n/a | 4 |
| Jan ’24 | n/a | €84.94 0% | 13.7% | €99.97 | €71.63 | n/a | 3 |
| Dec ’23 | n/a | €85.80 0% | 16.5% | €99.97 | €71.63 | n/a | 2 |
| Nov ’23 | n/a | €86.14 0% | 16.1% | €99.97 | €72.31 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$15.60
7D
-4.3%
1Y
72.6%
H. Lundbeck
DKK 42.0b
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
LUNB
DKK 5.90
7D
-2.2%
1Y
34.5%
Bayer
€19.0b
Operates as a life science company worldwide.
BAYN
€19.37
7D
-0.9%
1Y
-38.3%